drugset / Trial / NCT00531856

Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients

NCT00531856

Phase 2 Withdrawn Mallinckrodt
RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to evaluate the safety and tolerability of two carbon monoxide doses when administered as an inhaled gas for 1 hour in patients receiving kidney transplants.

Timeline

Start
2007-08
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbon Monoxide Other / unclassified 0.7 mg/kg Inhaled
Subject Carbon Monoxide Other / unclassified 2 mg/kg Inhaled
Subject Carbon Monoxide Other / unclassified 3 mg/kg Inhaled
Subject Carbon Monoxide Other / unclassified 3.5 mg/kg Inhaled

Indications

No indication recorded.